Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 275

1.

p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia.

Elf S, Blevins D, Jin L, Chung TW, Williams IR, Lee BH, Lin JX, Leonard WJ, Taunton J, Khoury HJ, Kang S.

Blood. 2011 Jun 23;117(25):6885-94. doi: 10.1182/blood-2010-10-315721. Epub 2011 Apr 28.

2.

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.

Weisberg E, Banerji L, Wright RD, Barrett R, Ray A, Moreno D, Catley L, Jiang J, Hall-Meyers E, Sauveur-Michel M, Stone R, Galinsky I, Fox E, Kung AL, Griffin JD.

Blood. 2008 Apr 1;111(7):3723-34. doi: 10.1182/blood-2007-09-114454. Epub 2008 Jan 9.

3.

Targeting RSK2 in myeloid leukemia: right for FLT3 but wrong for BCR-ABL.

Lee BH, Kang S.

Cell Cycle. 2011 Nov 1;10(21):3611-2. doi: 10.4161/cc.10.21.17833. Epub 2011 Nov 1. No abstract available.

PMID:
22033178
4.

Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations.

Alvarez-Calderon F, Gregory MA, Pham-Danis C, DeRyckere D, Stevens BM, Zaberezhnyy V, Hill AA, Gemta L, Kumar A, Kumar V, Wempe MF, Pollyea DA, Jordan CT, Serkova NJ, Graham DK, DeGregori J.

Clin Cancer Res. 2015 Mar 15;21(6):1360-72. doi: 10.1158/1078-0432.CCR-14-2146. Epub 2014 Dec 29.

5.

Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.

Adam M, Pogacic V, Bendit M, Chappuis R, Nawijn MC, Duyster J, Fox CJ, Thompson CB, Cools J, Schwaller J.

Cancer Res. 2006 Apr 1;66(7):3828-35.

6.

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.

Sattler M, Scheijen B, Weisberg E, Griffin JD.

Adv Exp Med Biol. 2003;532:121-40. Review.

PMID:
12908554
7.

Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3.

Fukuda S, Singh P, Moh A, Abe M, Conway EM, Boswell HS, Yamaguchi S, Fu XY, Pelus LM.

Blood. 2009 Jul 9;114(2):394-403. doi: 10.1182/blood-2008-11-188714. Epub 2009 May 1.

9.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.

J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29.

PMID:
18230792
10.

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K.

Blood. 2005 Feb 15;105(4):1768-76. Epub 2004 Oct 28.

11.
12.
14.

Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.

Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M.

Clin Cancer Res. 2014 May 1;20(9):2363-74. doi: 10.1158/1078-0432.CCR-13-2052. Epub 2014 Mar 11.

15.

Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis.

Griswold IJ, Shen LJ, La Rosée P, Demehri S, Heinrich MC, Braziel RM, McGreevey L, Haley AD, Giese N, Druker BJ, Deininger MW.

Blood. 2004 Nov 1;104(9):2912-8. Epub 2004 Jul 8.

16.

Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.

Yuan H, Wang Z, Li L, Zhang H, Modi H, Horne D, Bhatia R, Chen W.

Blood. 2012 Feb 23;119(8):1904-14. doi: 10.1182/blood-2011-06-361691. Epub 2011 Dec 29.

17.

Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.

Jacobi A, Thieme S, Lehmann R, Ugarte F, Malech HL, Koch S, Thiede C, Müller K, Bornhäuser M, Ryser M, Brenner S.

Exp Hematol. 2010 Mar;38(3):180-90. doi: 10.1016/j.exphem.2009.12.003. Epub 2009 Dec 24.

18.

FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment.

Cai D, Wang Y, Ottmann OG, Barth PJ, Neubauer A, Burchert A.

Blood. 2006 Mar 1;107(5):2094-7. Epub 2005 Nov 22.

20.

Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.

Lindner I, Kharfan-Dabaja MA, Ayala E, Kolonias D, Carlson LM, Beazer-Barclay Y, Scherf U, Hnatyszyn JH, Lee KP.

J Immunol. 2003 Aug 15;171(4):1780-91.

Supplemental Content

Support Center